{
  "_metadata": { "version": "2.1", "ticker": "ARGX", "asset_name": "ARGX-213", "extraction_date": "2026-02-11", "source_id": "argx_corporate_2026" },
  "asset": { "name": "ARGX-213", "company": "argenx SE", "ticker": "ARGX", "stage": "Phase 3 ready (Registrational)", "modality": "Antibody (FcRn-targeting with Fc-ABDEG and alpha-albumin VHH)", "ownership": null, "one_liner": "ARGX-213 is a next-generation FcRn molecule that achieves convenient monthly dosing with sustained IgG reduction of ~75-80%, designed to extend argenx's FcRn leadership across 15+ potential indications." },
  "target": { "name": "FcRn", "full_name": "Neonatal Fc Receptor", "class": "Receptor", "pathway": "IgG recycling / FcRn-mediated IgG homeostasis", "biology": { "simple_explanation": "Like efgartigimod, ARGX-213 blocks FcRn to reduce pathogenic IgG. However, its alpha-albumin VHH component extends its half-life, enabling sustained IgG reduction with convenient monthly dosing rather than the cyclical pattern seen with efgartigimod.", "pathway_detail": null, "downstream_effects": ["Sustained reduction of IgG levels", "Monthly dosing convenience"] }, "why_good_target": { "clinical_validation": "Efgartigimod (same target) approved in gMG and CIDP with $4.2B in 2025 sales; ARGX-213 achieves improved PD profile vs efgartigimod", "genetic_validation": { "gain_of_function": null, "loss_of_function": null }, "source": {"id": "argx_corporate_2026", "slide": 21, "verified": false} } },
  "mechanism": { "type": "FcRn blocker with extended half-life (Fc-ABDEG + alpha-albumin VHH)", "how_it_works": "ARGX-213 combines Fc-ABDEG technology (FcRn blocking) with an alpha-albumin VHH nanobody that binds albumin to extend the molecule's half-life, enabling sustained IgG reduction and convenient monthly dosing", "differentiation": "Achieves sustained ~75-80% IgG reduction vs efgartigimod's cyclical pattern; convenient monthly dosing achieved; designed for 15+ potential indications", "source": {"id": "argx_corporate_2026", "slide": 21, "verified": false} },
  "regulatory": { "designations": null, "planned_pathway": { "type": null, "surrogate_endpoint": null, "source": {"id": "argx_corporate_2026", "slide": null, "verified": false} } },
  "partnership": { "_note": "Elektrofi partnership for small volume delivery mentioned", "partner": "Elektrofi", "territory": null, "economics": null },
  "pharmacology": {
    "pk_parameters": { "half_life": { "value": null, "population": null, "source": {"id": "argx_corporate_2026", "slide": null, "verified": false} }, "cmax": { "value": null, "source": {"id": "argx_corporate_2026", "slide": null, "verified": false} }, "auc": { "value": null, "source": {"id": "argx_corporate_2026", "slide": null, "verified": false} }, "tmax": { "value": null, "source": {"id": "argx_corporate_2026", "slide": null, "verified": false} }, "bioavailability": { "value": null, "source": {"id": "argx_corporate_2026", "slide": null, "verified": false} }, "volume_of_distribution": { "value": null, "source": {"id": "argx_corporate_2026", "slide": null, "verified": false} } },
    "dose_response": { "doses_tested": null, "dose_rationale": null, "exposure_response": null, "recommended_dose": { "dose": "Monthly (convenient monthly dose achieved)", "rationale": "Alpha-albumin VHH extends half-life enabling monthly dosing", "source": {"id": "argx_corporate_2026", "slide": 21, "verified": false} }, "by_dose": null },
    "target_engagement": {
      "metric": "IgG change from baseline (%)",
      "by_dose": [ { "dose": null, "engagement": "IgG reduction curve shown (slide 21) â€” ARGX-213 achieves rapid ~-75-80% sustained IgG reduction from baseline maintained through 140 days, compared with efgartigimod which shows cyclical oscillation between ~-20% and ~-70%", "compartment": "blood", "source": {"id": "argx_corporate_2026", "slide": 21, "verified": false} } ]
    },
    "pk_summary": "Slide 21 shows ARGX-213 achieves sustained ~75-80% IgG reduction from baseline through 140 days with a convenient monthly dose, compared with efgartigimod's cyclical reduction pattern. Graph axes: Y-axis = IgG change from baseline (%), X-axis = time in days (0-140). ARGX-213 curve (green) drops rapidly to ~-75-80% and remains sustained; efgartigimod curve (blue) oscillates. No numeric PK values provided."
  },
  "indications": { "lead": { "name": null, "patient_population": null, "current_penetration": null, "rationale": "15+ potential indications across IgG-mediated diseases" }, "expansion": null },
  "clinical_data": { "trials": null, "_note": "Phase 1 data shown graphically (slide 21) but no trial details provided" },
  "differentiation_claims": [ { "claim": "Convenient monthly dose achieved vs efgartigimod's cyclical dosing", "evidence_level": "cross_trial", "caveat": "Comparison shown graphically (slide 21); different molecules and likely different trial populations; Phase 1 data only", "source": {"id": "argx_corporate_2026", "slide": 21, "verified": false} }, { "claim": "Sustained IgG reduction (~75-80%) vs efgartigimod's cyclical pattern", "evidence_level": "cross_trial", "caveat": "Graphical comparison only; numeric values estimated from graph", "source": {"id": "argx_corporate_2026", "slide": 21, "verified": false} } ],
  "competitive_landscape": { "competitors": null },
  "ip_landscape": { "composition_of_matter": { "patent_expiry": null, "source": {"id": "argx_corporate_2026", "slide": null, "verified": false} }, "method_of_use": { "patent_expiry": null, "source": {"id": "argx_corporate_2026", "slide": null, "verified": false} }, "regulatory_exclusivity": { "type": null, "expiry": null }, "freedom_to_operate": null },
  "market_opportunity": { "tam": null, "patient_population": "15+ potential indications", "unmet_need": "Need for sustained IgG reduction with convenient dosing", "pricing_benchmark": null, "peak_sales_estimate": null, "source": {"id": "argx_corporate_2026", "slide": 20, "verified": false} },
  "catalysts": null,
  "investment_analysis": { "probability_of_success": null, "key_risks": ["Phase 3 ready but no Phase 3 timeline provided", "May cannibalize efgartigimod franchise"], "bull_case": [ {"thesis": "Lifecycle extension for FcRn franchise with superior PD profile", "evidence": "Sustained vs cyclical IgG reduction (slide 21)", "confidence": "medium"} ], "bear_case": [ {"thesis": "Phase 1 data only; Phase 3 timeline and indications not specified", "evidence": "Slide 16 says Phase 3 ready but no timeline", "confidence": "medium"} ], "key_debates": null },
  "_extraction_quality": { "completeness_score": "low", "missing_critical_fields": ["PK numeric values", "Phase 3 timeline and indication", "Trial design details", "Safety data", "Dosing details beyond 'monthly'", "Regulatory designations", "IP/patents", "Market opportunity"], "recommended_supplementary_sources": ["ARGX-213 Phase 1 publication", "argenx R&D Day or investor presentations for Phase 3 plans", "Medical conference posters for full PK/PD data"] }
}
